Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model-Reference-Cited by-同舟云学术

Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model

Published:2021-12-21 Issue:12 Volume:4 Page:e2139573
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Filleron Thomas¹,Bachelier Marine¹,Mazieres Julien²,Pérol Maurice³,Meyer Nicolas⁴,Martin Elodie¹,Mathevet Fanny¹,Dauxois Jean-Yves⁵,Porcher Raphael⁶,Delord Jean-Pierre⁷

Affiliation:

1. Department of Biostatistics, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France

2. Department of Pneumology, Centre Hospitalier Universitaire de Toulouse Larrey, Toulouse, France

3. Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France

4. Institut Universitaire du Cancer Toulouse Oncopôle, Toulouse, France

5. Institut de Mathématiques de Toulouse, Université de Toulouse, Centre National de la Recherche Scientifique, Institut National des Sciences Appliquées de Toulouse, Toulouse, France

6. Assistance Publique des Hôpitaux de Paris, Hôpital Hôtel Dieu, Centre d’Épidémiologie Clinique, INSERM U1153, Paris, France

7. Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2787282/filleron_2021_oi_211112_1639430358.81384.pdf

Reference52 articles.

1. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.;Robert;Lancet Oncol,2019

2. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase iii trials (CheckMate 017 and CheckMate 057).;Horn;J Clin Oncol,2017

3. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.;Motzer;N Engl J Med,2018